Could a diabetes drug help teens with fatty liver?
NCT ID NCT03867487
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether empagliflozin, a drug used for diabetes, can help teens with non-alcoholic fatty liver disease (NAFLD) and obesity. Forty participants will take either the drug or a placebo for several weeks. The main goal is to see if the drug reduces liver fat measured by MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin (Jardiance)
What this could lead to
If successful, this could point toward a new treatment option for teens with fatty liver disease, potentially reducing liver fat and improving metabolic health.
What could go wrong
This is an early phase 2 trial with only 40 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects like dehydration or urinary infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, 60601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact